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Abstract
Background: Intracerebral hemorrhage (ICH) induces a series of inflammatory processes that contribute to
neuronal damage and neurological deterioration. Liver X receptors (LXRs) are nuclear receptors that negatively
regulate transcriptional processes involved in inflammatory responses, but their role in the pathology following ICH
remains unclear. The present study investigated the neuroprotective effects and anti-inflammatory actions of
TO901317, a synthetic LXR agonist, in a model of collagenase-induced ICH and in microglial cultures.
Methods: Mice subjected to collagenase-induced ICH injury were injected with either TO901317 (30 mg/kg) or
vehicle 10 min after ICH and subsequently daily for 2 days. Behavioral studies, histology analysis, and assessments of
hematoma volumes, brain water content, and blood-brain barrier (BBB) permeability were performed. The protein
expression of LXR-α, LXR-β, ATP binding cassette transporter-1 (ABCA-1), and inflammatory molecules was analyzed.
The anti-inflammatory mechanism of TO901317 was investigated in cultured microglia that were stimulated with
either lipopolysaccharide (LPS) or thrombin.
Results: ICH induced an increase in LXR-α protein levels in the hemorrhagic hemisphere at 6 h whereas LXR-β
expression remained unaffected. Both LXR-α and LXR-β were expressed in neurons and microglia in the peri-ICH
region and but rarely in astrocytes. TO901317 significantly attenuated functional deficits and brain damage up to
28 days post-ICH. TO901317 also reduced neuronal death, BBB disruption, and brain edema at day 4 post-ICH.
These changes were associated with marked reductions in microglial activation, neutrophil infiltration, and
expression levels of inflammatory mediators at 4 and 7 days. However, TO901317 had no effect on matrix
metalloproteinase-9 activity. In BV2 microglial cultures, TO901317 attenuated LPS- and thrombin-stimulated nitric
oxide production and reduced LPS-induced p38, JNK, MAPK, and nuclear factor-kappa B (NF-κB) signaling.
Moreover, delaying administration of TO901317 to 3 h post-ICH reduced brain tissue damage and neuronal death.
Conclusions: Our results suggest that enhancing LXR activation may provide a potential therapy for ICH by
modulating the cytotoxic functions of microglia.
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Background
Intracerebral hemorrhage (ICH) accounts for approxi-
mately 15 % of all strokes with high mortality and
morbidity [1]. ICH induces brain damage due to initial
tissue disruption from hematoma compression and sub-
sequent development of excitotoxicity, oxidative damage,
and inflammation [2, 3]. Of these, cerebral inflammation
is considered to be a key pathological factor of ICH-
induced brain damage and correlates with deterioration
and poor outcomes in patients [4]. Suppression of
inflammatory responses has also been reported to im-
prove both histological and functional outcomes and to
reduce brain edema in animal studies [5–8]. Inflamma-
tion after ICH involves infiltration of peripheral inflam-
matory cells, activation of microglia, and overproduction
of inflammatory mediators, such as cytokines, chemo-
kines, and matrix metalloproteases (MMPs) via nuclear
factor-kappa B (NF-κB) signaling [9]. These inflamma-
tory events may induce blood-brain barrier (BBB)
disruption and brain edema, which ultimately lead to
neuronal death and neurological deterioration [9]. Thus,
defining the signals that control cerebral inflammatory
responses has important implications for modulating
disease processes following ICH.
Liver X receptors (LXRs) are nuclear receptors that
regulate lipid metabolism at the transcriptional level
[10]. Two members of the LXR superfamily have been
identified, LXR-α and LXR-β, both of which are present
in the nervous system and which have highly similar
DNA or ligand-binding domains [10, 11]. LXRs can be
activated by natural ligands, such as oxysterols [12] or
by synthetic agonists [13]. The activation of LXRs regu-
lates the expression of several genes that are involved in
cholesterol metabolism [10]. In addition, LXRs nega-
tively regulate transcriptional processes that are involved
in inflammatory responses [10]. Previous in vitro studies
have shown that LXR agonists attenuate inflammation
by inhibiting NF-κB activity, and the expression of
inflammatory mediators, such as inducible nitric oxide
synthase (iNOS), cyclooxygenase-2 (COX-2), and pro-
inflammatory cytokines and chemokines in microglia
and astrocytes [14–16]. The anti-inflammatory activities
of LXRs have also been observed in animal models of
Alzheimer’s disease [17], Parkinson’s disease [18], spinal
cord injury [19], and cerebral ischemia [20, 21]. LXR
agonists also exert neuroprotection [20, 22, 23] and
attenuate functional deficits [20, 22, 24] in experi-
mental cerebral ischemia. However, no information is
available concerning the possible therapeutic efficacy
and anti-inflammatory activity of LXR activation after
hemorrhagic stroke.
The aim of the present study was to determine the
neuroprotective effect of LXR activation using a syn-
thetic agonist, TO901317, in a mouse model of ICH.
We also examined whether LXR activation attenuated




All animal protocols were carried out according to the
Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996), and were approved
by the Animal Research Committee at Cheng Hsin
General Hospital. Adult male C57BL/6J mice (age 8–10
weeks, weight 23–28 g) were kept at a constant
temperature (21–25 °C) under a 12-h light/dark cycle
with a humidity of approximately 45–50 %. Water and
pellet chow were provided ad libitum.
Experimental protocol
Mice were randomized into different treatment groups
by using computer-generated random numbers. All
outcome measurements and analyses described below
were performed in a blinded manner. Four studies were
conducted (Fig. 1). The first study examined the tem-
poral profile and cellular localization of LXR expression
after ICH. Assessment included western blots (n = 7/
group) and double immunofluorescence labeling (n = 6/
group). The second study evaluated the neuroprotective
effect of the synthetic LXR agonist TO901317, which
has been widely used in experimental studies and acti-
vates both LXR isoforms with similar potency [25].
TO901317 (30 mg/kg, Cayman Chemical, Ann Arbor,
MI, USA) dissolved in either 30 % dimethyl sulfoxide
(DMSO) (100 μL) or a corresponding volume of vehicle
(30 % DMSO) was administered intraperitoneally (ip)
10 min after ICH and subsequently daily for 2 days
(10 min, 24 h, and 48 h). Testing was as follows: (1) be-
havioral tests (n = 13/group); (2) metabolic characteris-
tics and histology (n = 5–7/group); (3) hemoglobin assay,
brain water content, and Evans Blue dye extravasation
(n = 6–8/group); and (4) western blot analysis (n = 6–8/
group). The dose and route of TO901317 were selected
based on previous work on experimental cerebral ische-
mia [20, 21, 23] and on our pilot study, in which con-
centrations of 20, 30, and 40 mg/kg were tested.
TO901317 at 30 and 40 mg/kg, but not at 20 mg/kg,
reduced ICH-induced behavioral deficits with equivalent
efficacy (Additional file 1: Figure S1). The three-dose
regimen was chosen because inflammatory-related signals
peak between 1 and 3 days after collagenase-induced ICH
and decline thereafter [26, 27].
The third study investigated the anti-inflammatory
effect of TO901317. Assessments included matrix
metalloproteinase-9 (MMP-9) zymography and west-
ern blot analysis, enzyme-linked immunosorbent assay
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(ELISA), and immunohistochemistry (n = 5–7/group).
The fourth study examined the delayed therapeutic poten-
tial of TO901317 for ICH. Either TO901317 or vehicle
was administered ip at 3 h following ICH and subse-
quently daily for 2 days (3, 27, and 51 h), and protective
effects were assessed using cresyl violet staining and
Fluoro-Jade B (FJB) histology (n = 7/group).
Intracerebral hemorrhage model
ICH model was performed as previously described [28].
Briefly, mice were placed into a stereotaxic frame after
anesthesia with sodium pentobarbital (65 mg/kg, ip; Rhone
Merieux, Harlow, UK). After retracting the scalp, a 30-
gauge needle attached to a Hamilton syringe was implanted
through a 1-mm-diameter burr hole into the right striatum
(stereotaxic coordinates: 0.8 mm anterior and 2.5 mm
lateral to bregma, 2.5 mm in depth). Bacterial collagenase
(type VII-S; Sigma, St. Louis, MO, USA; 0.15 U in 0.5 μL of
saline) was infused into the brain at a rate of 0.05 μL/min
over 10 min with an infusion pump to induce intracerebral
hemorrhage, and the needle was left in place for an add-
itional 20 min to prevent reflux. After removal of the nee-
dle, the craniotomy was sealed with dental cement and the
scalp was sutured closed. Mice were maintained at a 37.0 ±
0.5 °C body temperature using a heated pad throughout the
surgery and recovery period. Sham-operated mice received
an equal volume of normal saline in the same manner.
Metabolic characteristics assessment
Mice were anesthetized with an overdose of sodium
pentobarbital (200 mg/kg, ip), and right atrial puncture
was performed to collect venous blood. The collected
blood was centrifuged (3500 g for 5 min), and the serum
was stored on ice until analysis. Serum blood urea nitro-
gen (BUN), creatinine (CRE), alanine aminotransferase
(ALT), triglyceride (TG), and cholesterol (CHO) were
measured by a chemistry autoanalyzer (Synchron Clin-
ical System LX20; Beckman Coulter, Fullerton, CA,
USA) to assess renal, liver, and cholesterol metabolisms.
Behavioral testing
Behavioral recovery was assessed using modified neuro-
logical severity score (mNSS) test, rotarod test, and
beam walking test. Animals were pre-trained for 3 days
for both rotarod and beam walking tests.
Modified neurological severity score
The mNSS included motor, sensory, reflex, and balance
tests [29]. A higher score represented a more severe
injury. Neurological function was graded on a scale of
0–18 (normal score, 0; maximal deficit score, 18).
Rotarod test
An accelerating rotarod was used to measure motor
function and balance in mice [30]. The rotarod speed
Fig. 1 Experimental design and animal group classification. cICH collagenase-induced intracerebral hemorrhage, IF immunofluorescence staining,
TO TO901317, mNSS modified neurological severity score, BWC brain water content, FJB Fluoro-Jade B staining, WB western blot, CV cresyl violet,
IHC immunohistochemal staining, ELISA enzyme-linked immunosorbent assay
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was slowly increased from 6 to 42 rpm within 7 min,
and the time for mice to fall off was recorded.
Beam walking test
The test was used to evaluate fine motor coordination
and function by measuring the ability of the animals
to traverse an elevated narrow beam as described
previously [30].
For the rotarod and beam walking tests, three measure-
ments per trial were recorded 1 h before ICH (baseline)
and at 1, 4, 7, 14, 21, and 28 days after ICH.
Hemoglobin assay
The hemoglobin contents of ICH brains were quantified
using a spectrophotometric assay as previously described
[28]. Mice were transcardially perfused and both ipsilat-
eral and contralateral striatum regions were collected
following ICH. Distilled water (300 μL) was added to
each hemisphere, followed by homogenization for 30 s,
sonication on ice for 1 min, and centrifugation at
13,000 rpm for 30 min. Drabkin reagent (80 μL; Sigma)
was added to a 20-μL aliquot of supernatant (which
contained the hemoglobin) and allowed to stand for
15 min at room temperature. Optical density was then
measured at a wavelength of 545 nm to assess the
concentration of cyanmethemoglobin. To generate a
standard curve, blood was obtained by cardiac pu-
nctures in anesthetized control mice. Incremental
volumes of this blood (0, 0.5, 1.0, 2.0, 4.0, and 8.0 μL)
were then added to 300 μL of tissue lysate from a nor-
mal hemispheric sample.
Brain water content
Brain water content was used as a measure of brain
edema, which occurred because of BBB breakdown post-
ICH. Following terminal anesthesia, mice were decapi-
tated after ICH. The brains were immediately removed
and divided into five parts, consisting of the ipsilateral
and contralateral cortexes (CX), ipsilateral and contralat-
eral basal ganglia (BG), and the cerebellum (which
served as an internal control). Brain samples were
immediately weighed on an electric analytical balance to
obtain the wet weight and then dried at 100 °C for 24 h
to obtain the dry weight. The water content of each
sample was calculated using the following formula: [(wet
weight − dry weight)/wet weight] × 100 %.
Blood-brain barrier permeability
A 2 % solution of Evans Blue dye in normal saline
(4 mL/kg of body weight) was injected into the tail vein
and was allowed to circulate for 1 h. The mice were then
transcardially perfused with phosphate-buffered saline
(PBS) following terminal anesthesia, and samples from
both hemispheres were homogenized in 1000 μL of
trichloroacetic acid, sonicated, and centrifuged (15 min,
4500 rpm, 4 °C). The absorbance of each supernatant for
Evans Blue dye was measured at 620 nm using a spec-
trophotometer. Evans Blue dye concentrations were
calculated and expressed as micrograms per gram of
brain tissue against a standard curve.
Tissue processing and histology
Following terminal anesthesia, mice were transcardially
perfused with PBS and then 4 % paraformaldehyde after
ICH or sham surgery. Brains were removed, post-fixed
in 4 % paraformaldehyde overnight, cryoprotected with
30 % sucrose, and then sectioned coronally (10 μm) over
the entire region of injury.
Hemorrhagic injury and hemispheric enlargement
analysis
Injury volume, hemispheric atrophy, striatal atrophy, and
hemispheric enlargement ratios were quantified using
coronal sections stained with cresyl violet at 20 rostral-
caudal levels that were spaced 200 μm apart. Sections
were analyzed using ImageJ software version 1.48
(ImageJ, National Institutes of Health, Bethesda, MD,
USA). Volume measurement was computed by a
summation of the areas multiplied by the interslice
distance (200 mm). Hemispheric or striatal atrophy was
assessed using the following formula: ([Contralateral
hemisphere or striatal volume − ipsilateral hemisphere or
striatal volume]/contralateral hemisphere or striatal
volume) × 100 %. Hemispheric enlargement was assessed
using the following formula: ([ipsilateral hemisphere
volume − contralateral hemisphere volume]/contralateral
hemisphere volume) × 100 %. Analysis was performed by
two experimenters who were blinded to all animal
groups. Inter-rater reliability was within 10 %.
Double immunofluorescence
To assess the cellular localization of LXR-α and LXR-β,
double immunofluorescence labeling was performed by
simultaneous incubation of either mouse anti-LXR-α
(1:200; Abcam, Cambridge, MA, USA) or rabbit anti-
LXR-β (1:50; Santa Cruz Biotechnology, Santa Cruz, CA,
USA) with mouse anti-neuronal nuclei antigen (NeuN; a
neuronal marker; 1:100; Millipore, Billerica, MA, USA),
rabbit anti-microtubule-associated protein 2 (MAP2; a
neuronal marker; 1:200; Millipore), rat anti-glial fibrillary
acidic protein (GFAP; an astrocyte marker; 1:500;
Invitrogen, Camarillo, CA, USA), rabbit anti-ionized
calcium-binding adaptor molecule 1 (Iba-1; a microglia/
macrophage marker; 1:400; Wako, Richmond, VA, USA),
or rat anti-F4/80 (a microglia/macrophage marker;
1:400; Serotec, Düsseldorf, Germany) overnight at 4 °C.
Sections were then washed, incubated with Alexa Fluor
488- or Alexa Fluor 594-conjugated secondary antibodies
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(1:400; Molecular Probes, Eugene, OR, USA) for 2 h,
observed under a fluorescence microscope (Olympus
BX-51; Olympus, Tokyo, Japan), and photographed.
Immunohistochemistry
Immunohistochemical analyses were carried out as
previously described [31]. After quenching of endogen-
ous peroxidase activity and blocking of nonspecific bind-
ing, sections were allowed to react with the primary
antibodies (rabbit anti-myeloperoxidase [MPO; a neutro-
phil marker; 1:1000; Dako, Carpinteria, CA, USA], rabbit
anti-Iba-1 [a microglia/macrophage marker; 1:1000;
Wako], or rat anti-CD45 [a marker for microglia and all
blood-born leukocytes, including macrophages, mono-
cytes, neutrophils, and T cells; 1:100; BD Biosciences
Pharmigen, San Jose, CA, USA]) at 4 °C overnight.
Further colorimetric detection was processed according
to the instructions of a Vectastain Elite ABC Kit (Vector
Laboratories, Burlingame, CA, USA) with the use of
diaminobenzidine as a peroxidase substrate. The specifi-
city of the staining reaction was assessed in several
control procedures, including omission of the primary
antibody and substitution of the primary antibody with
non-immune rabbit serum.
Fluoro-Jade B histochemistry
FJB is a polyanionic fluorescein derivative that binds
with high sensitivity and specificity to degenerating
neurons. Briefly, sections were rehydrated in graded
ethanol solutions (75, 50, and 25 %, 5 min each) and
distilled water, incubated in 0.06 % KMnO4 for 10 min,
rinsed in distilled water for 2 min, incubated in a
0.0004 % solution of FJB (Chemicon, Temecula, CA,
USA) for 30 min, and observed under a fluorescence
microscope (Olympus) at 450–490 nm.
Quantification of FJB, Iba-1, MPO, and CD45 staining
For each animal, FJB, Iba-1, MPO, and CD45 staining or
double immunofluoresence for cellular markers and
LXRs were quantified on three consecutive sections
from the hemorrhagic core at the level of 0.24 mm from
the bregma. The number of positive cells was counted in
an area of 920 × 860 μm2 in 10–12 non-overlapping
fields immediately adjacent to the hematoma using a
magnification of ×200 as previously described [28, 32].
Iba-1-positive resting microglia/macrophages were de-
fined as resting if they contained relatively small cell
bodies (<7.5 μm in diameter) with long slender processes
[33]. Microglia were defined as activated when a cell
body increased in size compared to resting microglia
with short, thick processes and intense immunointensity.
Activated microglia/macrophages were defined based on
a combination of morphological criteria and a cell body
diameter cutoff of 7.5 μm. The total number of FJB-,
Iba-1-, and MPO-positive cells was expressed as the
mean number per field of view. Quantification of LXRs
in neurons or microglia was expressed as (LXR-stained
neurons or microglia/neurons or microglia) × 100 %.
Analysis was performed by two experimenters who were
blinded to all animal groups. Inter-rater reliability was
within 10 %.
Western blot
Samples were collected and western blot was performed
as previously described [28]. A 2-mm-thick coronal
section from the ipsilateral hemisphere was collected
following ICH or sham surgery. Equal amounts of pro-
tein (35 to 50 μg protein in 20 μL for tissue samples and
20 μg protein in 20 μL for cell lysates) were separated by
sodium dodecyl sulfate-polyacrylamide gels, transferred
to Immobilon-P membranes (Millipore), blocked using
5 % milk in PBS containing 0.1 % Tween-20, and probed
overnight at 4 °C with primary antibodies including
mouse anti-LXR-α (1:1000; Abcam), rabbit anti-LXR-β
(1:1000; Santa Cruz), mouse anti-ATP binding cassette
transporter-1 (ABCA-1; 1:1000; Abcam), mouse anti-iNOS
(1:200; Sigma), rabbit anti-COX-2 (1:1000; Cayman),
rabbit anti-NF-κB p65 (1:1000; Santa Cruz), rabbit
phospho-p38 (1:1000; Cell Signaling, Danvers, MA,
USA), rabbit total p38 (1:2000; Cell Signaling), rabbit
phospho-Jun amino-terminal kinases (JNK; Thr183/
Tyr185, 1:1000; Cell Signaling), rabbit total JNK
(1:2000; Cell Signaling), rabbit phospho-extracellular
signal-regulated kinases p44/42 (Erk p44/42; Thr202/
Tyr204, 1:1000; Cell Signaling), and rabbit total Erk
(1:2000; Cell Signaling). The membranes were then
incubated with horseradish peroxidase-linked anti-
rabbit or anti-mouse secondary antibodies (Santa Cruz
Biotechnology; 1:1000) for 1 h at 4 °C. Protein band
intensities were quantified using ImageJ software, and
the relative intensity of protein signals was normalized
to the corresponding β-actin intensity.
Gelatin zymography
Zymography was performed as previously described
[28]. Briefly, protein samples were equally loaded and
separated by a 10 % Tris-glycine gel with 0.1 % gelatin
as a substrate. After separation, the gel was washed in
distilled water twice for 30 min, re-natured for 1 h with
2.5 % Triton X-100 buffer at room temperature, and
incubated for 48 h with developing buffer (0.05 M Tris-
HCl, pH 7.5; 0.2 mol/L NaCl; 5 mmol/L CaCl2; 0.05 %
Brij-35; and 0.2 mmol/L NaN3) at 37 °C. Following this,
the gel was stained with 0.05 % Coomassie R-250 dye
(Sigma) for 30 min and appropriately de-stained. Gela-
tinolytic activity (MMP-9, 92 kDa) was determined as by
the appearance of clear bands at the appropriate
molecular weights.
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Enzyme-linked immunosorbent assay and nitrite assay
Protein samples were collected as in western blotting fol-
lowing ICH or sham surgery. Monocyte chemoattractant
protein-1 (MCP-1), macrophage inflammatory protein-2
(MIP-2), interleukin (IL)-6, and interleukin-1β (IL-1β)
were measured in brain homogenates or cell lysates
using a commercially available ELISA kit (R&D Systems,
Minneapolis, MN, USA). All samples and standards were
assayed in duplicate according to the manufacturer’s
instructions. Nitric oxide (NO) production was assessed
by measuring the nitrite levels of the culture supernatants
with Griess reagent (Sigma).
Microglial culture
The mouse microglial BV2 cell line was cultured in
Dulbecco’s modified Eagle’s media (DMEM; Gibco/BRL,
Bethesda, MD, USA) supplemented with 10 % heat-
inactivated fetal bovine serum (FBS; Gibco/BRL), 100 U/
mL penicillin and 100 μg/mL streptomycin in a humidi-
fied atmosphere of 5 % CO2 at 37 °C. BV2 microglia
were stimulated with either 0.1 μg/mL lipopolysacchar-
ide (LPS) or 10 U/mL thrombin in the absence or
presence of varying concentrations of TO901317 for
24 h. The experiments were repeated four times with
different batches of cultures.
Statistical analyses
All data are presented as the mean and standard error of
the mean (mean ± SEM). One-way or two-way analysis
of variance (ANOVA) followed by post hoc Bonferroni
evaluation was used for multiple groups to determine
significant differences. Student’s t test was used to test the
differences between two groups. Statistical significance
was set at P < 0.05.
Results
Increased LXR-α protein expression in mice after ICH
We first examined the temporal profiles and cellular
localizations of LXRs following ICH in mice. ICH
induced an increase in LXR-α protein levels in the
hemorrhagic hemisphere at 6 h (284 % of the sham
level; P = 0.019), 1 day (272 %; P = 0.038) and 4 days
(277 %; P = 0.029), whereas LXR-β expression remained
mostly unaffected (Fig. 2a, b). Because LXR-α expression
peaked at 6 h after collagenase-induced ICH, we investi-
gated the cellular localizations of LXRs at this time point.
Dual-label immunofluorescence demonstrated that both
LXR-α and LXR-β were mainly expressed in neurons and
microglia in the peri-ICH region and rarely in astrocytes
(Fig. 2c, d). Quantification results showed that in the
vehicle-treated ICH group, 44.1 ± 1.5 % of neurons were
positive for LXR-α and 67.1 ± 1.9 % of neurons were posi-
tive for LXR-β. For microglia/macrophages, 26.2 ± 1.2 %
were positive for LXR-α and 24.4 ± 2.2 % were positive for
LXR-β. Similarly, in the TO901317-treated group,
42.0 ± 1.2 % of neurons were positive for LXR-α and
64.1 ± 0.7 % of neurons were positive for LXR-β. For
microglia/macrophages, 26.1 ± 1.2 % were positive for
LXR-α and 24.8 ± 0.6 % were positive for LXR-β. There
was no difference between the vehicle and TO901317-
treated groups for the ratios of LXR-positive neurons
or microglia.
TO901317 improved long-term neurobehavioral function
but did not alter hemorrhage size in mice after ICH
To investigate the protective efficacy of LXR activation
in ICH, TO901317 was employed to activate LXR
following ICH. We first assessed the safety of TO901317
in mice on the 4th day post-ICH, at which point one
dose of either vehicle or TO901317 was administered
daily for 3 days. Treatment with TO901317 did not alter
plasma concentrations of BUN and CRE, which are indi-
cators of renal function, ALT, an indicator of hepatic
function, or TG and CHO, which are indicators of chol-
esterol metabolism (Table 1). Similarly, no significant
between-group differences were found in body weight
change at 28 days (Fig. 3a) or in brain hemoglobin
content, an indicator of hemorrhage size, at 4 days
(Fig. 3b). We then assessed the protective effects of
TO901317 on behavioral recovery following ICH using
three different behavioral tests. The extent of global
neurological deficit was evaluated by mNSS. At 2 h after
injury, there was no difference in mNSS between
vehicle-treated and TO901317-treated groups, indicating
that injury severity was initially similar regardless of
treatment (Fig. 3c). Significant improvement in neuro-
logical function was observed from 4 to 28 days in the
TO901317 group compared with the vehicle group (all
P < 0.05; Fig. 3c). Rotarod and beam walking tests were
employed to evaluate motor and coordination functions.
The TO901317 group had better rotarod performance
compared to that of the vehicle group at 4, 14, 21, and
28 days (all P < 0.01; Fig. 3d). Likewise, beam walk laten-
cies were shorter in the TO901317 group from 1 to
14 days (all P < 0.05; Fig. 3e).
TO901317 ameliorated brain tissue loss and neuronal
damage in mice after ICH
To determine whether the above changes in behav-
ioral function reflected in a reduction of brain tissue
damage and neuronal death, histological outcomes
were evaluated. ICH induced pronounced loss of tis-
sue in the hemorrhagic hemisphere and striatum at
day 28 post-ICH (Fig. 4a). However, TO901317 sig-
nificantly reduced the degree of hemispheric atrophy
(2.5 ± 1.5 % versus 10.4 ± 0.7 %, P < 0.001; Fig. 4a) and
striatal atrophy compared to vehicle (11.6 ± 2.6 %
versus 31.9 ± 4.0 %, P = 0.0029) at 28 days. We further
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evaluated whether TO901317 attenuated brain tissue
damage and neuronal injury during the earlier stage of
ICH. Consistent with the protective effect at 28 days,
TO901317 treatment significantly reduced hemorrhagic
injury volume to 69 % of the vehicle group (9.5 ± 1.3 mm3
versus 13.9 ± 1.3 mm3, P = 0.047; Fig. 4b) at 4 days.
Hemispheric enlargement, an indicator of brain edema,
was also significantly smaller in TO901317-treated mice
(4.1 ± 0.8 %) than in vehicle-treated mice (8.5 ± 1.4 %,
P = 0.02; Fig. 4b) at 4 days. Moreover, TO901317
significantly attenuated hemorrhagic injury volume at
both 7 (0.9 ± 0.2 mm3 versus 3.5 ± 0.6 mm3, P < 0.001;
Fig. 4c) and 14 days (0.4 ± 0.2 mm3 versus 1.8 ± 0.6 mm3,
P = 0.0426; Fig. 4d). At 7 and 14 days after ICH, tissue loss
was primary in the ipsilateral striatum, and the total hemi-
spheric atrophy was more evident at 28 days. TO901317
significantly reduced the degree of striatal atrophy at 7
(2.7 ± 1.5 % versus 7.9 ± 0.6 %, P = 0.0133; Fig. 4c) and
14 days (6.7 ± 2.5 % versus 19.8 ± 2.6 %, P = 0.0066;
Fig. 4d). In parallel with the effect of brain tissue
Fig. 2 Expression and cellular distribution of LXR-α and LXR-β receptor isoforms in mouse brains subjected to ICH. Representative immunoblots
and quantitative data of a the LXR-α and b LXR-β protein levels in the ipsilateral (hemorrhagic) hemispheres from ICH or sham-operated mice
after collagenase injection. Bar graphs of densitometric analysis of bands show a significant increase in LXR-α protein levels in the ipsilateral
hemispheres of ICH mice at 6 h, 1 day, and 4 days post-ICH, compared with the sham-operated mice. LXR-β expression remained unaffected after
ICH. Values are mean ± SEM; *P < 0.05 versus sham group (n = 7 mice/group, one-way ANOVA). c LXR-α and d LXR-β in the peri-hematomal area
observed by immunofluorescence labeling. LXRs are shown in green, and immunolabeling of MAP 2 or NeuN (neurons), Iba-1 or F4/80 (microglia),
or GFAP (astrocytes) is shown in red. Yellow labeling (white arrows) indicates co-localization. Both LXR-α and LXR-β were mainly expressed in
neurons and microglia and rarely in astrocytes. Sections were stained with DAPI (blue) to show all nuclei. The scale bar is 100 μm. Values are
mean ± SEM (n = 6 mice/group, Student’s t test)
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protection, TO901317 significantly attenuated the number
of FJB-positive degenerative neurons around the
hematoma when compared to vehicle administration
at 4 days post-ICH (54.3 ± 4.3 versus 111.3 ± 7.6 cells/field,
P < 0.001; Fig. 4e).
TO901317 attenuated brain edema and BBB permeability
in mice after ICH
We next explored whether TO901317 influenced
ICH-induced brain edema and BBB breakdown as
both are consequences of inflammatory responses
following hemorrhagic stroke [34]. Brain water
content was significantly increased in the ipsilateral
hemisphere in the vehicle group compared with the
contralateral counterpart (82.0 ± 0.5 % versus 78.4 ±
0.6 %; P < 0.001) at 4 days post-ICH, which was sig-
nificantly decreased with TO901317 treatment (79.2
± 0.3 % versus 82.0 ± 0.5 %, P < 0.001; Fig. 4f ). To
further examine the effects of TO901317 on BBB
permeability, we used Evans Blue dye as a marker
for albumin extravasation. ICH resulted in signifi-
cantly increased Evans Blue extravasation in the
hemorrhagic hemisphere compared to the contralateral
side at 4 days post-ICH (19.2 ± 0.7 versus 4.9 ±
0.4 μg/g, P < 0.001; Fig. 4g). However, TO901317
administration resulted in attenuated levels of
extracted Evans Blue compared to vehicle-treated
mice at 4 days (13.5 ± 1.0 versus 19.2 ± 0.7 μg/g, P < 0.001;
Fig. 4g).
TO901317 activated the LXR target gene ABCA-1 in mice
after ICH
To determine whether TO901317 acted through LXR,
we examined the expression levels of LXRs and their
target gene ABCA-1 in ICH following the administra-
tion of TO901317. ICH induced a significant increase
in LXR-α protein expression compared to the sham
control at day 4, whereas LXR-β expression remained
unchanged (Fig. 5a, b). Both LXR-α and LXR-β
protein levels were unaltered in the ICH mice after
TO901317 treatment compared with vehicle treat-
ment. However, the protein level of ABCA-1, a re-
presentative LXR-regulated gene, was significantly
elevated following TO901317 administration at day 4
post-ICH (P = 0.019; Fig. 5c). These results suggest
that brain LXRs were activated in a ligand-dependent
manner after ICH.
Fig. 3 TO901317 improved neurobehavioral function but did not alter body weight or hemorrhage size after ICH. a There were no significant
differences in body weight between the control (vehicle-treated) and 30 mg/kg TO901317-treated groups before or at 28 days after ICH. b Hemoglobin
levels in vehicle-treated and TO901317-treated mice were not significantly different at 4 days post-ICH. Treatment with 30 mg/kg TO901317 (compared
with vehicle) significantly c reduced the modified neurological severity score (mNSS) from 4 to 28 days (all P< 0.05), d improved the rotarod performance
at 4, 14, 21, and 28 days (all P< 0.01), and e reduced the beam walk traversing time from 1 to 14 days (all P< 0.05) post-ICH. Values are mean ± SEM;
#P< 0.05, ##P< 0.01, and ###P< 0.001 versus vehicle group (n= 13 mice/group, Student’s t test for body weight; n= 8 mice/group, Student’s t test for
hemoglobin assay; n= 13 mice/group, repeated measures two-way ANOVA for behavioral tests)
Table 1 Metabolic characteristics of the mice treated with
vehicle and TO901317 30 mg/kg
ICH day 4
Vehicle TO901317 30 mg/kg Reference range
BUN (mg/dL) 20.60 ± 2.45 18.48 ± 3.92 8–33
CRE (mg/dL) 0.06 ± 0.02 0.05 ± 0.02 0.2–0.9
ALT (mg/dL) 25.00 ± 4.53 29.20 ± 4.47 17–77
TG (mg/dL) 78.00 ± 18.02 62.20 ± 28.79 60–160
CHO (mg/dL) 74.60 ± 12.46 73.40 ± 19.57 90–170
Values are expressed as means ± SEM. n = 5 mice/group [31, 57]
ICH intracerebral hemorrhage, BUN blood urea nitrogen, CRE creatinine, ALT
alanine aminotransferase, TG triglyceride, CHO cholesterol
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Fig. 4 TO901317 attenuated brain tissue and neuronal damage reduced brain edema and BBB disruption after ICH. Representative cresyl
violet-stained brain sections of vehicle-treated and 30 mg/kg TO901317-treated mice at a 28, b 4, c 7, and d 14 days post-ICH. Analysis of lesion
volumes demonstrates that 30 mg/kg TO901317 significantly reduced hemispheric and striatal atrophy at 28 days and significantly reduced
hemorrhagic injury volume and hemispheric enlargement at 4 days. TO901317 also attenuated hemorrhagic injury volume and striatal atrophy at
7 and 14 days. The scale bar is 2 mm. e Representative FJB-stained sections of a sham-injured, a vehicle-treated, and a 30 mg/kg TO901317-treated
mouse at 4 days post-ICH. The inset is a representative FJB-positive cell at higher magnification. Quantification analysis shows that TO901317
significantly reduced the number of degenerating neurons at 4 days post-ICH. The scale bar is 100 μm. f Brain water content in the ipsilateral basal
ganglion of vehicle-treated mice was significantly higher than in the contralateral basal ganglion at 4 days post-ICH. In the ipsilateral basal ganglion,
brain water content of 30 mg/kg TO901317-treated mice was significantly lower than in vehicle-treated mice. Cont-BG contralateral basal ganglia,
Cont-CX contralateral cortex, Ipsi-BG ipsilateral basal ganglia, Ipsi-CX ipsilateral cortex. g TO901317 (30 mg/kg) significantly decreased leakage of Evans
Blue dye into the brain in the ipsilateral hemisphere compared with the vehicle-treated mice. Values are mean ± SEM; ***P < 0.001 versus contralateral
hemisphere, #P < 0.05, ##P < 0.01, and ###P < 0.001 versus vehicle group (n = 6–8 mice/group, Student’s t test)
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TO901317 attenuated neutrophil infiltration, microglial
activation, and macrophage infiltration but did not affect
MMP-9 activity in mice after ICH
We next evaluated degrees of neutrophil infiltration and
microglial activation to determine the anti-inflammatory
activity of TO901317. ICH resulted in an accumulation
of neutrophils in the peri-hematoma area at 4 days (34.0
± 2.1 cells/field) and 7 days (38.5 ± 5.6 cells/field), and
TO901317 treatment significantly reduced this response
(21.4 ± 1.6 cells/field at 4 days, P < 0.001; 11.4 ± 2.2 cells/
field at 7 days, P = 0.0011; Fig. 6a). The infiltrated neu-
trophils were nearly absent in the peri-hematoma area at
14 days. The number of total microglia/macrophages
(Iba-1-positive) cells in the hemorrhagic brain also sig-
nificantly increased compared with the sham group
(38.8 ± 2.2 cells/field) in the peri-hematoma area at both
4 days (69.2 ± 1.6 cells/field) and 7 days (87.9 ± 3.7 cells/
field; Fig. 6b). On the other hand, animals who received
TO901317 treatment showed significant reductions in
the total number of Iba-1-positive cells at both 4 days
(54.1 ± 3.5 cells/field, P = 0.002) and 7 days (66.1 ± 4.9
cells/field, P = 0.005) following ICH. There was no
difference between the vehicle and TO901317-treated
groups at 14 days (35.1 ± 3.8 versus 33.7 ± 3.1 cells/field,
P = 0.785). There was also a large number of activated
microglia/macrophages in the peri-hematoma area at 4
and 7 days after ICH, which was scant at 14 days.
TO901317 significantly reduced the number of activated
Iba-1-positive cells at 4 days (28.6 ± 3.1 cells/field versus
43.1 ± 4.0 cells/field, P = 0.013, Fig. 6b) and 7 days (22.2
± 3.2 cells/field versus 43.8 ± 1.9 cells/field, P < 0.001).
However, TO901317 treatment did not affect the
number of resting microglia at both 4 and 7 days. We
then used CD45 staining, an antigen associated with
microglia and all leukocytes, including macrophages,
monocytes, neutrophils, and T cells, to identify inflam-
matory cells. The expression of CD45 is low in resting
microglia and increases during microglial activation,
whereas CD45 expression is high in blood-born mono-
cytes [35, 36]. Similarly, TO901317 treatment signifi-
cantly reduced the number of CD45-positive cells in the
peri-hematoma area at 4 days (22.6 ± 1.7 cells/field
versus 30.6 ± 0.5 cells/field, P = 0.0043; Fig. 6c) and 7 days
(21.5 ± 1.0 cells/field versus 25.7 ± 1.3 cells/field, P = 0.0256)
compared with the control group. Both activated Iba-1-
and CD45-positive cells were scant at 14 days following
ICH. We further analyzed MMP-9 activity, which mediates
BBB breakdown by degrading the basal lamina and contrib-
utes to the pathophysiology of ICH. MMP-9 activity was
significantly increased at 4 days post-ICH, but there was no
difference in MMP-9 activity between vehicle-treated and
TO901317-treated mice (Fig. 6d).
TO901317 reduced expression of inflammatory mediators
in mice after ICH
We then assessed whether TO901317 influenced the ex-
pression of inflammatory mediators following ICH. ICH
induced an increase in MCP-1, MIP-2, and interleukin-6
(IL-6) protein expression in hemorrhagic hemispheres at
4 and 7 days, but treatment with TO901317 significantly
reduced the MCP-1, MIP-2, and IL-6 levels at both
4 days (MCP-1: 33.1 ± 2.7 versus 52.1 ± 4.2 pg/mg
protein, P = 0.001; MIP-2: 5.5 ± 1.9 versus 13.4 ± 1.8 pg/
mg protein, P = 0.009; IL-6: 8.6 ± 2.5 versus 23.9 ± 2.8 pg/
mg protein, P < 0.001; Fig. 7a, b, c) and 7 days (MCP-
1: 23.7 ± 1.6 versus 41.8 ± 4.9 pg/mg protein, P =
0.003; MIP-2: 5.0 ± 2.5 versus 11.8 ± 1.8 pg/mg protein, P
= 0.003; IL-6: 9.3 ± 1.2 versus 24.3 ± 1.4 pg/mg protein, P <
0.001; Fig. 7a, b, c). Similarly, ICH-induced increases in
iNOS and COX-2 levels were significantly attenuated by
TO901317 treatment. Protein levels of iNOS and COX-
2 in TO901317-treated hemorrhagic hemispheres were
35 % (P = 0.02) and 42 % (P = 0.035) of the vehicle
groups, respectively (Fig. 7d, e).
Fig. 5 TO901317 did not affect LXR expression but increased the LXR target gene, ABCA-1 protein expression post-ICH. Representative immunoblots
of a LXR-α, b LXR-β, and c ABCA-1 proteins in the ipsilateral hemisphere of sham-injured, vehicle-treated, and 30 mg/kg TO901317-treated mice at
4 days post-ICH. Bar graphs of densitometric analysis of bands show that TO901317 did not affect either LXR-α or LXR-β protein expression
but increased the LXR target gene, ABCA-1 protein expression. Values are mean ± SEM; **P < 0.01, and ***P < 0.001 versus sham group, #P < 0.05
versus vehicle group (n = 5–7 mice/group, one-way ANOVA for LXRs and Student’s t test for ABCA-1 western blot).
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TO901317 attenuated LPS- and thrombin-induced
pro-inflammatory responses in cultured microglia
Our in vivo results demonstrated that TO901317 pre-
served neuronal function and reduced microglia activa-
tion after ICH; thus, we next used mouse BV2 microglial
cells to elucidate the underlying molecular mechanisms.
We used LPS, a strong immunostimulant, and thrombin,
a component of coagulation cascade that is rapidly
released following ICH, to activate microglia. The expos-
ure of BV2 microglial cells to LPS for 24 h led to an
increase in NO release in the culture supernatant, but
co-treatment with 1, 5, 10, or 50 μM TO901317 for 24 h
Fig. 6 TO901317 reduced neutrophil infiltration and microglial activation but had no effect on MMP-9 activity. Representative a MPO-stained,
b Iba-1-stained, and c CD45-stained brain sections from sham-injured, vehicle-treated, and 30 mg/kg TO901317-treated mice at 4, 7 and 14 days
post-ICH. Cell count analysis shows that TO901317-treated mice had significantly fewer MPO-positive, total Iba-1-positive, activated Iba-1-positive,
and CD45-positive cells than vehicle-treated mice in the peri-hematoma area at 4 and 7 days post-ICH. The number of MPO-positive, Iba-1-positive,
and CD45 positive cells is expressed as the mean number per field of view (0.8 mm2). The scale bar is 100 μm. d Representative zymography of
MMP-9 activity from a sham-injured control, a vehicle-treated, and a 30 mg/kg TO901317-treated mouse at 1 day post-ICH. There was no difference
in MMP-9 activity between vehicle-treated and TO901317-treated mice. Values are mean ± SEM; *P < 0.05 versus sham group, #P < 0.05, ##P < 0.01, and
###P < 0.001 versus vehicle group (n = 6–7 mice/group, Student’s t test for MPO, Iba-1, and CD45 immunohistochemistry; n = 6 mice/group, one-way
ANOVA for MMP-9 zymography)
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significantly reduced LPS-induced NO production to 58,
57, 48, and 60 % of that observed for the vehicle control
group, respectively, and 10 μM TO901317 provided the
highest degree of anti-inflammatory action (all P < 0.001;
Fig. 8a). Therefore, a dosage of 10 μM was employed for
subsequent biochemical studies. Similar results were ob-
served after thrombin stimulation (all P < 0.001; Fig. 8b).
Treatment with 10 μM TO901317 also significantly atten-
uated LPS-induced production of IL-1β (11.0 ± 1.3 versus
24.0 ± 0.7 pg/mg; P < 0.001; Fig. 8c), IL-6 (13.0 ± 0.2 versus
25.8 ± 0.6 pg/mg; P < 0.001; Fig. 8c), and MIP-2 (9.2 ± 0.1
versus 29.4 ± 0.3 pg/mg; P < 0.001; Fig. 8c) as measured in
the supernatants of microglial cultures.
We further investigated whether TO901317 influenced
the activation of NF-κB, a major transcription factor that
regulates pro-inflammatory gene expression and can be
activated by mitogen-activated protein kinases (MAPKs),
a family of serine/threonine protein kinases that mediate
microglial activation [37]. Nuclear NF-κB p65 levels
were low in the control group under basal (unstimu-
lated) conditions. Activation of NF-κB, as indicated by
nuclear translocation of p65, was observed at 1, 3, 6, and
24 h following LPS stimulation (all P < 0.001; Fig. 8d).
Co-treatment with 10 μM TO901317 significantly atten-
uated the LPS-induced increased nuclear levels of NF-
κB at 1 h (69 % of vehicle level, P = 0.004), 3 h (73 % of
vehicle level, P = 0.042), and 6 h (61 % of vehicle
level, P = 0.011) after LPS stimulation (Fig. 8d).
Previous report studies have shown that MAPKs play
critical roles in harmful microglial activation during
acute brain injury [37]. Therefore, we evaluated the
inhibitory effects of TO901317 on LPS-induced activa-
tion of MAPKs, including p38, JNK, and Erk. Stimula-
tion of microglia with LPS resulted in rapid activation of
p38, JNK, and Erk. Co-treatment with 10 μM TO901317
significantly reduced LPS-induced p38 and JNK phos-
phorylation at 3 and 6 h (all P < 0.05; Fig. 8d). However,
there was no difference in the phosphorylation of Erk
between TO901317-treated and vehicle-treated groups
(all P > 0.05; Fig. 8d). Together, these results suggest that
TO901317 may inhibit reactive microglial activation and
subsequently attenuate the production of pro-inflammatory
mediators by suppressing p38 and JNK signaling pathways
and NF-κB activation.
Fig. 7 TO901317 reduced expression of inflammatory mediators in mice after ICH. Bar graphs of a MCP-1, b MIP-2, and c IL-6 protein concentrations,
as assessed by ELISA in ipsilateral hemispheres of sham control, vehicle-treated, and 30 mg/kg TO901317-treated mice at 4 and 7 days
post-ICH. TO901317-treated mice exhibited significantly reduced MCP-1, MIP-2, and IL-6 protein levels compared with vehicle-treated mice
at 4 and 7 days. Representative immunoblots of d iNOS and e COX-2 proteins in ipsilateral hemispheres of sham control, vehicle-treated, and 30 mg/kg
TO901317-treated mice at 4 days post-ICH. Bar graphs of densitometric analysis of bands show a significant decrease of iNOS and COX-2 protein levels in
ipsilateral hemispheres of TO901317-treated mice, compared with vehicle-treated mice. Values are presented as means ± SEM; **P< 0.01 and ***P< 0.001
versus sham control; #P< 0.05, ##P< 0.01, ###P< 0.001 versus vehicle group (n= 6–7 mice/group, one-way ANOVA)
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Delayed administration of TO901317 reduced brain
damage and neuronal death
To determine whether TO901317 still exerts neuroprotec-
tive effects when administered at later time points after
ICH, TO901317 treatment was delayed by 3 h post-injury.
TO901317 treatment at 3 h significantly reduced injury
volume (9.3 ± 0.9 mm3 versus 14.0 ± 1.1 mm3; P < 0.001;
Fig. 9a) and hemispheric enlargement, an indicator of
brain edema (5.3 ± 1.0 % versus 10.5 ± 1.2 %, P = 0.0068;
Fig. 9a) at 4 days. The number of FJB-positive neurons
Fig. 8 TO901317 inhibited LPS- and thrombin-induced inflammatory responses in cultured microglia. In BV2 microglia, co-treatment of 1, 5, 10, or
50 μM TO901317 with LPS or thrombin for 24 h significantly attenuated a LPS- or b thrombin-induced release of NO from the supernatant of
microglial cultures. c Co-treatment of 10 μM TO901317 with LPS for 24 h significantly reduced LPS-induced release of IL-1β, IL-6, and MIP-2 from
the supernatant of BV2 microglial cultures. d Representative immunoblots and bar graphs show that co-treatment of 10 μM TO901317 with LPS
significantly reduced LPS-induced p65 nuclear translocation at 1, 3, and 6 h, p38 and JNK phosphorylation at 3 and 6 h but did not affect Erk
phosphorylation in BV2 microglia. Values are presented as mean ± SEM of four independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001
versus normal control; #P < 0.05, ##P < 0.01, and ###P < 0.001 versus LPS or thrombin stimulation alone (one-way ANOVA)
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around the peri-hematoma area was also reduced
(53.9 ± 3.1 versus 100.9 ± 4.0 cells/field; P < 0.001; Fig. 9b)
compared to the vehicle at day 4 post-injury. The neuro-
protective effects of TO901317 treatment either immedi-
ately after or at 3 h after ICH were similar; injury volume,
hemispheric enlargement, and neuronal damage were
attenuated by 31, 52, and 51 % when administered
immediately post-ICH (Fig. 4) and by 34, 50, and
47 % when treatment started at 3 h post-injury,
respectively (Fig. 9).
Discussion
In this study, we provide the first evidence that activa-
tion of LXRs with the synthetic ligand TO901317
improved behavioral outcomes and attenuated brain
edema in mice subjected to ICH. Brain tissue damage,
neuronal death, and BBB disruption were also reduced
following TO901317 treatment. This neuroprotection
was observed in conjunction with a reduction of micro-
glial activation, neutrophil infiltration, and expression of
inflammatory molecules. Mechanistically, TO901317 at-
tenuated LPS- and thrombin-stimulated NO production
in BV2 microglia, which was associated with reduced acti-
vation of p38, JNK, MAPK, and NF-κB signaling in LPS-
stimulated microglia. Notably, TO901317 was still neuro-
protective when using a more clinically relevant treatment
time window. Our results suggest that enhancing LXR
activation may provide a potential therapy for ICH by
modulating the cytotoxic functions of microglia.
We found that LXR-α is selectively upregulated by
ICH, although both LXR-α and LXR-β subtypes were
detected in the normal brain. Our findings are in agree-
ment with previous reports showing that LXR-α is the
form that is predominantly induced in response to a
deleterious stimulus such as cerebral ischemia [20] or
myocardial ischemia/reperfusion injury [38]. While
previous evidence has demonstrated that both LXR-α
and LXR-β mediate anti-inflammatory action [39], LXR-
α is more responsive in controlling the production of
inflammatory molecules compared to LXR-β [40]. On
the other hand, whereas LXR-α is expressed predomin-
antly in liver, kidney, intestine, and tissue macrophages,
LXR-β is highly expressed in the brain [10, 11]. The
importance of LXR-β in brain function is supported by
previous studies showing that LXR-β deficiency is asso-
ciated with central nervous system pathologies and brain
development abnormalities [18, 41–43]. For example,
LXR-β expression is essential to the formation of the
cerebral cortex via its role in guiding the migration of
later-born neurons during corticogenesis [41] and is also
involved in white matter development and myelination
[43]. LXR-β knockout mice exhibit degeneration of
motor neurons in the spinal cord and of dopaminergic
neurons in the substantia nigra [42]. Furthermore, LXR-
β deletion aggravates the loss of dopaminergic neurons
in the substantia nigra in an animal model of Parkinson’s
disease [18]. Therefore, the specific roles of the individ-
ual LXR subtypes in ICH require further clarification.
We showed that TO901317 reduced activation of micro-
glia and ICH-induced upregulation of inflammatory mole-
cules (e.g., MCP-1, MIP-2, IL-6, COX-2, and iNOS) in
hemorrhagic brain. In parallel with these in vivo results,
TO901317 suppressed LPS- and thrombin-induced
production of inflammatory mediators and LPS-induced
activation of p38, JNK, and NF-κB pathways in BV2
microglia. Our results suggest a direct effect of LXRs
on microglial activation and p38 phosphorylation. Most
importantly, we demonstrated that the LXR ligand
Fig. 9 Delayed TO901317 treatment attenuated injury volume, hemispheric enlargement, and neuronal death after ICH. a Representative cresyl
violet-stained brain sections of a vehicle-treated and a delayed 30 mg/kg TO901317-treated mouse at 4 days post-ICH. Analysis of lesion volumes
demonstrates that treatment with 30 mg/kg TO901317 at 3 h post-ICH significantly reduced hemorrhagic injury volume and hemispheric enlargement
at 4 days. The scale bar is 2 mm. b Representative FJB-stained sections of a sham-injured, a vehicle-treated, and a delayed 30 mg/kg TO901317-treated
mouse at 4 days post-ICH. The inset is a representative FJB-positive cell at higher magnification. Quantification analysis shows that treatment with
30 mg/kg TO901317 at 3 h post-ICH significantly reduced the number of degenerating neurons at 4 days post-ICH. The scale bar is 100 μm. Values are
presented as means ± SEM; ##P < 0.01 and ###P < 0.001 versus vehicle group (n = 7 mice/group, Student’s t test)
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attenuated inflammation in microglia that were acti-
vated by thrombin, which is rapidly produced following
ICH and contributes to ICH-induced brain damage [2].
Our findings are in line with previous studies showing
that LXR activation suppresses inflammatory responses
in animal models of CNS diseases [17–20, 22] and in
cultured microglia stimulated with LPS or IL-1β [14–16].
LXRs have been reported to deactivate microglia from an
amoeboid, active form to a ramified, resting configuration
[44]. Following ICH, microglia are activated and then
mediate neuroinflammatory responses via producing mul-
tiple inflammatory molecules [9], which can activate
receptor-dependent apoptotic pathways and contribute to
neuronal damage [45]. Experimental evidence has further
shown that blocking microglial activation protects
against ICH-induced brain damage [46, 47]. In our
study, TO901317 reduced neuronal damage at 4 days
post-ICH and diminished neurological deficits and de-
creased brain atrophy at 28 days following ICH. These
findings correlated with a reduction of microglia activa-
tion in hemorrhagic brain. Thus, it seems very likely that
LXR activation may limit brain damage following ICH, in
part by blocking microglial activation and attenuating the
production of pro-inflammatory mediators.
Our results demonstrated that TO901317 reduced
neutrophil infiltration and BBB disruption but did not
affect MMP-9 activity. This reduction of infiltrating
neutrophils is consistent with previous studies in which
TO90317 decreased neutrophil recruitment significantly
in damaged spinal cord [19] and lung tissue [48]. The
protective effect of TO901317 on neutrophil infiltration
may be attributed to a reduction of pro-inflammatory
chemokines, which are involved in BBB disruption and
the migration of peripheral immune cells into hemorrhagic
brain [9]. It is also possible that TO901317 exerts a direct
effect on neutrophil responses because a recent study re-
ports that LXR signaling controls peripheral neutrophil
homeostasis via regulation of neutrophil clearance and
cytokine expression [49]. In contrast with previous reports
showing that pharmacological activation of LXRs reduced
MMP-9 protein expression following cerebral ischemia [20]
and suppressed MMP-9 mRNA and protein expression in
macrophages [39], we found that MMP-9 activity was not
altered by TO901317 after ICH. One possible ex-
planation for this disparity is that because MMP-9
gene expression is regulated by both NF-κB and acti-
vator protein-1 (AP-1) activities [50], antagonism of
NF-κB signaling by TO901317 may not be able to
suppress AP-1-dependent MMP-9 activity. Another ex-
planation is the time point that was examined. We mea-
sured MMP-9 activity at day 4, which is not the peak time
point of MMP-9 activation after ICH. Cerebral MMP-9
levels were reported to peak in a bimodal pattern after
ICH, with the first peak occurring during days 1–3 and
the second peak occurring around day 7 [51]. Indeed, our
findings are consistent with previous neuroprotective
studies showing that minocycline significantly reduced
neuroinflammation and BBB disruption but did not affect
MMP-9 levels [27, 52].
Apart from these anti-inflammatory actions, LXRs
may provide neuroprotection via other mechanisms. For
example, LXR activation by GW3965, a synthetic LXR
agonist, suppressed brain beta-amyloid (Aβ) accumula-
tion in a model of mild traumatic brain injury (TBI) in
which cerebral inflammation is not significant [53]. This
result suggests that the beneficial effects of LXR agonists
on mild TBI recovery may be independent from their
anti-inflammatory effects. Other studies further show
that LXR agonists modulate the deposition and clearance
of Aβ metabolism and attenuate Alzheimer’s pathology
both in vivo and in vitro [15, 54, 55]. In addition to
regulating Aβ metabolism, the LXR agonist TO901317
promoted synaptic plasticity and axonal regeneration fol-
lowing experimental cerebral ischemia and increased
neurite outgrowth by increasing PI3K signaling in hypoxic
cortical neurons [21]. The activation of LXR signaling
also protected cultured neurons from oxidative damage-
induced toxicity [56]. Furthermore, TO901317 was re-
ported to promote angiogenesis and vascular maturation
through eNOS following cerebral ischemia [24]. Whether
LXRs exert direct actions on neurons or vessels following
ICH warrants further investigation.
Conclusions
In conclusion, we demonstrated that activation of LXRs
by T0901317 reduced functional deficits and brain tissue
damage and attenuated neuroinflammation following
ICH. T0901317 also reduced activation of p38, JNK,
MAPK, and NF-κB signaling in cultured microglia. Con-
sidering the extended therapeutic window of T0901317
and its long-lasting effects, our results suggest that
pharmacological enhancement of LXRs may have a role
as a therapeutic intervention in ICH.
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Additional file 1: Figure S1. Effects of 3 different doses of TO901317
on collagenase-induced ICH in mice. (A) In all treatment groups, the
mNSSs were significantly lower than the vehicle group at 4 and 7 days
post-ICH. (B) There was no significant difference between the 20 mg/kg
TO901317-treated and vehicle-treated groups at all tested time points in
the rotarod test. Treatment with 30 mg/kg and 40 mg/kg TO901317
significantly improved rotarod performance compared with the vehicle-
treated group at all tested time points following ICH. (C) There was no
significant difference between the 20 mg/kg TO901317-treated and
vehicle-treated groups at all tested time points in the beam walk test.
Beam walk latencies were significantly shorter for both the 30 mg/kg and
40 mg/kg groups than the vehicle group at all tested time points
following ICH. Values are presented as mean ± SEM; #P < 0.05, ##P < 0.01,
and ###P < 0.001 versus vehicle group (n = 12 mice/group, repeated
measures two-way ANOVA) (TIFF 1107 kb)
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